Company Profile

Cytori Therapeutics Inc (AKA: MacroPore Inc~MacroPore Biosurgery, Inc.)
Profile last edited on: 1/17/19      CAGE: 4AW88      UEI: NUN2VLR3MZD6

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1996
First Award
2004
Latest Award
2007
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3020 Callan Road
San Diego, CA 92121
   (858) 458-0900
   info@cytori.com
   www.cytori.com
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Formerly known as MacroPore, Inc. and MacroPore Biosurgery, Inc. - the latter traded on the Frankfort Exchange (XMP) , Cytori Therapeutics, Inc. engages in developing and commercializing stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery, and serious, chronic, and life threatening conditions. Cyrtori has developed the Celution® System family of medical devices and instruments which are being sold in the European and Asian cosmetic and reconstructive surgery markets. Regulatory approval for the devices are being sought in the United States. Cytori's StemSource® product line is sold globally for cell banking and research applications. In addition, it operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Cytori Therapeutics also manufactures macropore biosurgery products that include HYDROSORB family of spine and orthopedic implant products and thin film bioresorbable soft tissue separation implant products. It has strategic joint venture with Olympus Corporation to develop to manufacture future generation devices based on its Celution system. Besides its headquarters in San Diego, California, Cytori also maintains offices in Switzerland, Japan, and India

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
75-99
Revenue Range
7.5M-10M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : CYTX
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 1 NIH $249,877
Project Title: Adipose Tissue-Derived Cells for Vascular Cell Therapy
2005 2 NIH $950,042
Project Title: Adipose Derived Cell Therapy for Myocardial Infarction

Key People / Management

  Christopher J Calhoun -- CEO

  John K Fraser